Paper

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Published Jul 28, 2020 · R. Lees, Ali Mofeez, Jane Kinghorn

The lancet. Psychiatry

122

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Rigorous Journal

Highly Cited

Study Snapshot

Cannabidiol 400 mg and 800 mg were found to be safe and more effective than placebo in reducing cannabis use in individuals with cannabis use disorder.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

References

Citations